Cardiovascular Sciences, Inc. Enters Into Agreement With Medical Technologies Enterprises, Inc.
27 February 2008 - 2:26AM
Marketwired
ORLANDO, FL , a corporation under the laws of Nevada and a
client company of the High Technology Incubator at the University
of Central Florida, is proud to announce that it has reached a
partnership agreement with Medical Technologies Enterprises, Inc.
of Palm Harbor, FL. Cardiovascular Sciences, Inc. is researching
and developing its proprietary technology designed to address a
need for a better and more effective product to prevent
post-surgical adhesions and its complications.
Medical Technologies Enterprises, Inc.'s founder and president,
Mr. Eric O. Edelmann, has extensive experience as a business
development consultant, serving many Fortune 500 companies over
more than 35 years. His firm, Strategic Futures International,
Inc., boasts many clients, ranging from the local companies in the
area up to global conglomerates. Medical Technologies Enterprises,
Inc. was founded as a retail enterprise to market various
proprietary and generic items, including some medical supplies,
various medical testing kits and as well as an assorted array of
supplements.
"We see several advantages to such a strategic partnership,"
explains Cardiovascular Sciences, Inc.'s CEO, Dr. Larry Hooper.
"Initially, there will be an economy resulting from sharing many of
the administrative operations of the two companies. Second, it
gives us a retail presence in the marketplace and on the web. It is
seldom that a company, at this stage in the development of its
primary medical technology, has a revenue generating retail market
presence."
Similarly enthusiastic, Medical Technologies Enterprises, Inc.'s
Eric Edelmann exclaims, "This joint agreement gives both companies
a presence and access to the entire path from development to
market, from bench to bedside so to speak."
John Martin, who was recently appointed to the board of
Cardiovascular Sciences, Inc., has extensive experience with
formulating and marketing various supplement lines. "I see this as
an excellent way to create and grow a significant revenue stream at
a very early stage. Additionally, it will diversify the company's
profit centers as Cardiovascular Sciences, Inc. continues to
develop it's proprietary medical technologies." Mr. Martin has a
proven track record in developing and marketing successful health
enhancement strategies and supplements.
Both companies are excited about the possibilities this
represents and the likely beneficial impact it will have, not just
on the near term financials, but also in the longer term as it
allows for an equity-sparing stepping up the pace of development of
Cardiovascular Sciences, Inc.'s anti-adhesion technology and allows
Medical Technologies Enterprises, Inc.'s access to and early entry
into markets with needs addressed by this technology and other
related technologies.
About Cardiovascular Sciences
Cardiovascular Sciences, Inc. is an advanced medical device
company which is developing a novel technology platform to address
the problem of post-surgical and post-traumatic adhesions.
Adhesions and the complications of adhesions are a significant
problem worldwide for a wide range of specialists, including
general surgeons, cardiothoracic surgeons, orthopedic, plastic, and
ophthalmologic and otolaryngology specialists to name just some of
them. In addition, the veterinary field has a tremendous need for a
product that can prevent similar problems in a wide variety of
animals.
The Company's unique materials and processes promise a more
cost-effective and decidedly more efficient and capable means to
deal with a problem that has been so devastating to so many.
Current sponsored research at the University of Central Florida
(UCF) and previously at other institutions indicate that The
Company is on the right path and progressing well.
In addition to the anti-adhesion technology, The Company owns
technology in a variety of other areas, including thrombo-resistant
coatings, enhanced intra-arterial balloon pumping catheters, cell
engineered vascular tissues, and a method for improved recovery of
the heart following cardioplegia. This yields a diversified
portfolio with projects in various stages of development.
www.cvsciences.org
Forward-looking statements in this release are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
certain risks, and uncertainties and actual results could differ
from those discussed. This material is information only and is not
an offer or solicitation to buy or sell the securities.
For more information contact: Cardiovascular Sciences Investor
Relations 800-858-7502 ir@cvsciences.org
Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Feb 2024 to Feb 2025
